Director Chu Shelley's first open-market purchase: 11,111 shares at $18.00 as three insiders buy within 14 days
Director Chu Shelley made her first open-market purchase of Odyssey Therapeutics shares, departing from a history of only receiving stock-based compensation. This purchase occurs within a broader window in which three insiders have bought shares across a 14-day span, a pattern that stands out given the company's minimal trading history. The stock is trading near its listing price, having appreciated modestly since debut. Shelley's decision to deploy personal capital into the stock—rather than relying solely on compensation grants—adds a layer of distinction to her position as a board member, though the data does not indicate why she chose to buy at this particular time.